Kymera Therapeutics, Inc. has appointed Felix J. Baker, PhD, as Chairman of its Board of Directors, effective immediately. Dr. Baker succeeds Bruce Booth, DPhil, who served as Chairman since co-founding the company in 2016 and will remain an Independent Director. The leadership change comes as Kymera advances multiple mid- to late-stage programs and expands its oral degrader pipeline.

Nello Mainolfi, PhD, Founder, President and CEO of Kymera Therapeutics, highlighted Dr. Baker's strategic contributions since joining the board in 2024. Dr. Baker has served as Kymera’s Lead Independent Director and is a Managing Member of Baker Brothers Investments, which he co-founded in 2000. He holds a BS and a PhD in Immunology from Stanford University and serves on the boards of several biopharmaceutical companies, including BeOne Medicines Ltd., Bicycle Therapeutics PLC, Kodiak Sciences, Inc., and Kiniksa Pharmaceuticals International, plc.

Dr. Booth was credited for guiding Kymera from an emerging technology to a clinical-stage organization. The company, founded in 2016, focuses on developing oral small molecule degrader medicines for immunological diseases using targeted protein degradation (TPD) technology.

Board Composition

Kymera Therapeutics is a clinical-stage biotechnology company deploying TPD to address disease targets inaccessible with conventional therapeutics. The company has advanced the first degrader into the clinic for immunological diseases and aims to build an industry-leading pipeline of oral small molecule degraders.

Kymera Therapeutics presented positive Phase 1 results for KT-621, its first-in-class oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association (JDA) Annual Meeting held June 11-14, 2026, in Kyoto, Japan. The data demonstrated a favorable safety profile and pharmacokinetic/pharmacodynamic (PK/PD) results consistent with previously reported KT-621 clinical studies. These findings support the global advancement of KT-621 for chronic Type 2 inflammatory diseases, including atopic dermatitis and asthma.

The randomized, double-blind, placebo-controlled Phase 1 study enrolled 24 healthy Japanese adults across two dose levels. Participants were randomized 3:1 to receive KT-621 or placebo once daily for seven days. The trial was designed to provide the PK/PD and safety data required by regulators prior to enrolling patients in Japan for global KT-621 Phase 2b studies.

KT-621 demonstrated rapid absorption and dose-proportional increases in plasma exposure. The drug achieved rapid, sustained STAT6 degradation in blood, with median degradation of at least 98% at both dose levels by Day 7. The treatment was well tolerated with a favorable safety profile, matching results seen in non-Japanese adults and atopic dermatitis patients. The company has previously reported positive Phase 1 data for KT-621 in non-Japanese healthy volunteers and patients with moderate to severe atopic dermatitis, showing robust reductions in disease-relevant Type 2 inflammatory biomarkers.

Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, stated that the consistency across KT-621 Phase 1 studies reflects the strong translation of this approach from preclinical to clinical settings. He emphasized the potential of KT-621 to transform care for patients with chronic Type 2 inflammatory conditions through a novel oral treatment option.

Parallel Phase 2b trials for KT-621 are currently underway. The BROADEN2 trial focuses on atopic dermatitis, while the BREADTH trial targets asthma. Data from these studies are expected by mid-2027 and late 2027, respectively. These trials aim to accelerate development for subsequent parallel Phase 3 registration studies across multiple Type 2 inflammatory diseases.

The oral presentation at JDA was titled "KT-621, an Oral, Once Daily STAT6 Degrader: PK, PD and Safety in Healthy Japanese Adults." Sagar Agarwal, PhD, Vice President of Clinical Pharmacology at Kymera Therapeutics, delivered the presentation on June 12, 2026.